MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program Mar 2, 2022 07:35AM
MINDCURE Hires Dr. Clare Purvis from Headspace to the position of Chief Product Officer to Advance Mental Health Digital Therapeutics Platform Feb 3, 2022 07:35AM
MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022 Jan 25, 2022 07:22PM
MINDCURE to Participate in the H.C. Wainwright Bioconnect Conference in January 2022 Jan 6, 2022 07:35AM
MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial Deployment in the Second Quarter of 2022 Dec 16, 2021 07:35AM


Dec 14, 2021 07:35AM MINDCURE Appoints Dr. Doron Sagman as Chief Medical Officer
Dec 2, 2021 07:00PM MINDCURE to Participate in Upcoming Conferences in December 2021
Nov 4, 2021 07:35AM MINDCURE Provides Update on Studies and Clinical Trials
Oct 28, 2021 07:35AM MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE's Digital Therapeutics P
Oct 27, 2021 07:35AM MINDCURE Announces Participation at Upcoming Events in November 2021
Oct 7, 2021 07:35AM MINDCURE to Webcast Live at the KCSA Psychedelics Virtual Investor Conference on October 13, 2021
Sep 30, 2021 07:10AM MINDCURE Announces Commencement of Trading on the OTCQX Best Market
Sep 28, 2021 03:30AM MINDCURE to Present at the Benzinga Healthcare Small Cap Conference
Sep 27, 2021 03:30AM MINDCURE Launches "Desire Project" To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy
Sep 23, 2021 03:30AM MINDCURE Signs Exclusive Digital Clinical Data Licensing Agreement with ATMA Journey Centers
Sep 22, 2021 03:30AM MINDCURE Announces Inclusion in AdvisorShares Psychedelics ETF
Sep 17, 2021 03:30AM MINDCURE to Participate in Maxim Group LLC's Advances in Mental Health Virtual Conference
Sep 16, 2021 03:30AM MINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental Health Industry
Sep 9, 2021 03:30AM MINDCURE Announces Platinum Sponsorship of the 2021 SANA Symposium
Sep 8, 2021 03:30AM MINDCURE to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Aug 31, 2021 08:38PM MINDCURE Announces Financial Results for Fiscal 2021
Aug 26, 2021 03:30AM MINDCURE Reaches Milestone, Releasing First of its Kind Mental Health Digital Therapeutics Platform to Partner Clinics in North America
Aug 10, 2021 03:30AM MINDCURE Welcomes Dr. Ken Weingardt, Digital Therapy Visionary, as a Senior Clinical Technology Advisor to its Psychedelic Digital Therapeutics Team
Aug 4, 2021 03:30AM MINDCURE Appoints Jerry White, Award-Winning Humanitarian Activist Who Shares in the 1997 Nobel Peace Prize, as Company Advisor
Jul 27, 2021 03:30AM MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research
Jul 13, 2021 03:30AM MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company's First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound
Jul 12, 2021 08:30AM MINDCURE Adopts Advance Notice Policy
Jun 17, 2021 03:30AM MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression
Jun 3, 2021 03:30AM MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research